FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approved BluePoint Laboratories' supplemental application for Imatinib Mesylate (ANDA 212773), approving a generic version of the cancer drug. Imatinib is u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

SUPPL AP for IMATINIB MESYLATE (IMATINIB MESYLATE)